Table 4

Variable overview

Study visit

1

2

3

4

5

6

7

8

9

10

Comment

Week

-5t1/2

0

1

2

3

4

5

6

26

30-52 1)

1) in euthymic phase

Test


Informed consent

X

Diagnostic interview

SCID or MINI plus

X

Inclusion/exclusion criteria

X

NORBRAIN Entry Questionnaire NEQ

Socio demography Medical history etc

X

PANSS

X

GAF

X

X

X

X

Clinical examination

X

Current and concomitant medication

X

X

X

X

X

X

X

X

X

X

Health related Quality of Life

SF 36

X

X

X

X

Efficacy

MADRS

X

X2)

X

X

X

X

X

X2)

X

X

2) audio taped

IDS

X

X2)

X

X

X

X

X

X2)

X

X

2) audio taped

CGI-BP

X

X

X

X

X

X

X

X

X

X

PGI-I

X

X

X

X

X

X

X

X

YMRS

X

X

X

X

X

X

X

X

X

X

MSIF

X

X

X

Relapse

Interview

X

X

Overall cognitive function

MMS 3)

X

X

X

X

X

X

X

3) in ECT-group only

Neuropsychological assessment

X

X

X

X

EMQ

X

X

X

X

Adverse events

Interview UKU

X4)

X

X

4) previous med.

SAE-form

X

X

X

X

X

X

Lab

Cytokines

X

X

X

X

Cortisol 5)

X

5) morning cortisol in blood

Other, incl cortisol6)

X

6) as specified in Blood samples

ECG 7)

X

7) if indicated

EEG

X

MRI caput

X

Substance abuse

Urin

X

Pregnancy

Urin 8)

X

8) fertile woman

Compliance

Interview

X

X

X

X

X

X

X

X

Compliance

Blood sample

X

Temperament

TEMPS-A

X

Migrene

Interview

X

X


Kessler et al. BMC Psychiatry 2010 10:16   doi:10.1186/1471-244X-10-16

Open Data